Overview
- Autolus reported Q4 2025 net product revenue of $23.3 million, a net loss of $90.3 million, and year‑end cash of $300.7 million.
- The company kept its 2026 AUCATZYL revenue target at $120 million to $135 million and said higher treatment volumes should turn gross margin positive in 2026.
- The first patient received AUTO8 in the Phase 1 ALARIC study for light‑chain amyloidosis, with initial data planned by the end of 2026.
- Executives said AUCATZYL generated $74.3 million in 2025 revenue and that 67 U.S. treatment centers were active by year‑end, with a goal of more than 80 in 2026 and an early U.K. launch underway.
- The AUCATZYL label warns of serious risks, including immune effector cell‑associated neurotoxicity syndrome reported in 64% of treated patients with 12% at grade 3 or higher, which doctors must monitor and manage.